Patel, Nikunj
Maher, Joshua
Lie, Xandra
Gwaltney, Chad
Barzi, Afsaneh
Karwal, Mark
Macarulla, Teresa
Sun, Hui-Chuan
Trojan, Jörg
Meyers, Oren
Workman, Christina
Morgan, Shethah
Negro, Alejandra
Cohen, Gordon
Funding for this research was provided by:
AstraZeneca.
Article History
Accepted: 1 June 2021
First Online: 11 June 2021
Declarations
:
: NP, CW, SM, AN, and GC are employees of AstraZeneca and hold shares in AstraZeneca. JM, XL, and OM are employees of IQVIA, which received funds from AstraZeneca to conduct the analysis of the study data. CG received consulting fees from IQVIA to participate in the design, execution, and analysis of this study. AB reports having no conflict of interest. MK has reported no conflicts of interest for this manuscript. TM reports consultancy/advisory role with Amgen, Baxter, Celgene, Incyte, Q&D Therapeutics, Serviere, Shire; research funding from AstraZeneca, BeiGene, Celgene. HCS received consultation honoraria/lecture fees from AstraZeneca, Eisai, MSD, Bayer, Roche, Hengrui, Innovent, and TopAlliance. JT has received consultation honoraria/lecture fees from AstraZeneca, BMS, Eisai, MSD, Merck Serono, Lilly, Ipsen, and Roche and has received grants from Ipsen and Roche.
: The study was approved by the New England Institutional Review Board.
: All study participants provided their written informed consent.